The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization
Open accessAbstract
The use of nanotechnology in medicine has the potential to have a major impact on human health for the prevention, diagnosis, and treatment of diseases. One particular aspect of the nanomedicine field which has received a great deal of attention is the design and development of nanoparticulate nanomedicines (NNMs) for drug delivery (i.e., drug-containing nanoparticles). NNMs are intended to deliver drugs via various mechanisms: solubilization, passive targeting, active targeting, and triggered release. The NNM approach aims to increase therapeutic efficacy, decrease the therapeutically effective dose, and/or reduce the risk of systemic side effects. In order to move a NNM from the bench to the bedside, several experimental challenges need to be addressed. This review will discuss the current trends and challenges in the clinical translation of NNMs as well as the potential pathways for translational development and commercialization. Key issues related to the clinical development of NNMs will be covered, including biological challenges, large-scale manufacturing, biocompatibility and safety, intellectual property (IP), government regulations, and overall cost-effectiveness in comparison to current therapies. These factors can impose significant hurdles limiting the appearance of NNMs on the market, irrelevant of whether they are therapeutically beneficial or not.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · cited 2×
“Potential reasons for this discrepancy have previously been reviewed (Sawant and Torchilin, 2012; Allen and Cullis, 2013), and include factors such as target accessibility and expression, disease-dependent anatomical and physiological barriers, and formulation stability.”
BackgroundDrug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552 · cited 1×
“In the last several decades, the application of nanotechnology for medical purposes has received significant attention from researchers, academia, funding agencies, government, and regulatory bodies (Allen and Cullis, 2004; Sercombe et al., 2015; Hare et al., 2017).”
BackgroundBertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Nanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,632
Self-citationRegulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Green Synthesis of Metallic Nanoparticles: Applications and Limitations
Dikshit, P., Kumar, J., Das, A., Sadhu, S., Sharma, S., Singh, S., Gupta, P., & Kim, B. (2021) · Catalysts · doi:10.3390/catal11080902 · Cited by 882
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Cancer treatment therapies: traditional to modern approaches to combat cancers
Kaur, R., Bhardwaj, A., & Gupta, S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08809-3 · Cited by 561
Nanoparticles in the Treatment of Infections Caused by Multidrug-Resistant Organisms
Lee, N.-Y., Ko, W.-C., & Hsueh, P.-R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01153 · Cited by 532
Hua, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00524 · Cited by 527
Self-citationNanoparticles: Taking a Unique Position in Medicine
Joseph, T., Kar Mahapatra, D., Esmaeili, A., Piszczyk, Ł., Hasanin, M., Kattali, M., Haponiuk, J., & Thomas, S. (2023) · Nanomaterials · doi:10.3390/nano13030574 · Cited by 480
Clinical translation of nanomedicines: Challenges, opportunities, and keys
Younis, M. A., Tawfeek, H. M., Abdellatif, A. A. H., Abdel-Aleem, J. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114083 · Cited by 462
DNA Vaccines—How Far From Clinical Use?
Hobernik, D., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113605 · Cited by 457
Effects of nanoparticle size, shape, and zeta potential on drug delivery
Öztürk, K., Kaplan, M., & Çalış, S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124799 · Cited by 449
Zhang, D., Ma, X.-L., Gu, Y., Huang, H., & Zhang, G.-W. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00799 · Cited by 436
RetractedAghebati‐Maleki, A., Dolati, S., Ahmadi, M., Baghbanzhadeh, A., Asadi, M., Fotouhi, A., Yousefi, M., & Aghebati‐Maleki, L. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29126 · Cited by 417
Understanding ligand-protected noble metal nanoclusters at work
Matus, M. F., & Häkkinen, H. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00537-1 · Cited by 356
Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery
Majumder, J., & Minko, T. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1828339 · Cited by 348
Eleraky, N. E., Allam, A., Hassan, S. B., & Omar, M. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020142 · Cited by 342
Mba, I. E., & Nweze, E. I. (2021) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-021-03070-x · Cited by 321
Nanocarriers for ocular drug delivery: current status and translational opportunity
Gorantla, S., Rapalli, V. K., Waghule, T., Singh, P. P., Dubey, S. K., Saha, R. N., & Singhvi, G. (2020) · RSC Advances · doi:10.1039/d0ra04971a · Cited by 313
PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up
Operti, M. C., Bernhardt, A., Grimm, S., Engel, A., Figdor, C. G., & Tagit, O. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120807 · Cited by 302
The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy
Francia, V., Schiffelers, R. M., Cullis, P. R., & Witzigmann, D. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00366 · Cited by 299
The Promise of Nanotechnology in Personalized Medicine
Alghamdi, M. A., Fallica, A. N., Virzì, N., Kesharwani, P., Pittalà, V., & Greish, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050673 · Cited by 284
Ahlawat, J., Guillama Barroso, G., Masoudi Asil, S., Alvarado, M., Armendariz, I., Bernal, J., Carabaza, X., Chavez, S., Cruz, P., Escalante, V., et al. (2020) · ACS Omega · doi:10.1021/acsomega.0c01592 · Cited by 274
Microneedle array systems for long-acting drug delivery
Vora, L. K., Moffatt, K., Tekko, I. A., Paredes, A. J., Volpe-Zanutto, F., Mishra, D., Peng, K., Raj Singh Thakur, R., & Donnelly, R. F. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.12.006 · Cited by 270
Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery
Waheed, S., Li, Z., Zhang, F., Chiarini, A., Armato, U., & Wu, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01605-4 · Cited by 259
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Self-citationFolic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems
Narmani, A., Rezvani, M., Farhood, B., Darkhor, P., Mohammadnejad, J., Amini, B., Refahi, S., & Abdi Goushbolagh, N. (2019) · Drug Development Research · doi:10.1002/ddr.21545 · Cited by 255
Therapeutic and Diagnostic Potential of Exosomes as Drug Delivery Systems in Brain Cancer
Avgoulas, D. I., Tasioulis, K. S., Papi, R. M., & Pantazaki, A. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051439 · Cited by 57
Unraveling the Role of the Tumor Extracellular Matrix to Inform Nanoparticle Design for Nanomedicine
Cassani, M., Fernandes, S., Pagliari, S., Cavalieri, F., Caruso, F., & Forte, G. (2025) · Advanced Science · doi:10.1002/advs.202409898 · Cited by 48
Riaz, S., Ali, S., Summer, M., Akhtar, U., Noor, S., Haqqi, R., Farooq, M. A., & Sardar, I. (2025) · Annals of Biomedical Engineering · doi:10.1007/s10439-025-03712-3 · Cited by 38
Ultrasmall silica nanoparticles in translational biomedical research: Overview and outlook
Singh, N., Shi, S., & Goel, S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114638 · Cited by 35
Metadata
- Authors
- Hua, S., de Matos, M. B. C., Metselaar, J. M., & Storm, G.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-07-17
- Volume
- 9
- Pages
- 790-790
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2810420630
- Cited by
- 1,048
- References
- 102
- FWCI
- 26.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.